Acute and persistent responses after H5N1 vaccination in humans.

Autor:	Apps R; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Biancotto A; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Candia J; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Kotliarov Y; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA., Perl S; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Cheung F; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Farmer R; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Mulè MP; Multiscale Systems Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; NIH Oxford-Cambridge Scholars Program, Cambridge Institute for Medical Research and Department of Medicine, University of Cambridge, UCB2 0QQ Cambridge, UK., Rachmaninoff N; Multiscale Systems Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Chen J; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Martins AJ; Multiscale Systems Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Shi R; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Zhou H; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Bansal N; Multiscale Systems Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Schum P; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Olnes MJ; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Milanez-Almeida P; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Han KL; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Sellers B; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Cortese M; Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA., Hagan T; Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA., Rouphael N; Hope Clinic of the Emory Vaccine Center, Decatur, GA 30030, USA., Pulendran B; Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA; Hope Clinic of the Emory Vaccine Center, Decatur, GA 30030, USA., King L; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993 USA., Manischewitz J; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993 USA., Khurana S; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993 USA., Golding H; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993 USA., van der Most RG; GSK, Rixensart, Belgium., Dickler HB; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA., Germain RN; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA; Lymphocyte Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Schwartzberg PL; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA; Cell Signaling and Immunity Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Tsang JS; NIH Center for Human Immunology, NIH, Bethesda, MD 20892, USA; Multiscale Systems Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; Center for Systems and Engineering Immunology, Departments of Immunobiology and Biomedical Engineering, Yale University, New Haven, CT 06520, USA. Electronic address: john.tsang@yale.edu.
Jazyk:	angličtina
Zdroj:	Cell reports [Cell Rep] 2024 Sep 24; Vol. 43 (9), pp. 114706. Date of Electronic Publication: 2024 Sep 04.
DOI:	10.1016/j.celrep.2024.114706
Abstrakt:	To gain insight into how an adjuvant impacts vaccination responses, we use systems immunology to study human H5N1 influenza vaccination with or without the adjuvant AS03, longitudinally assessing 14 time points including multiple time points within the first day after prime and boost. We develop an unsupervised computational framework to discover high-dimensional response patterns, which uncover adjuvant- and immunogenicity-associated early response dynamics, including some that differ post prime versus boost. With or without adjuvant, some vaccine-induced transcriptional patterns persist to at least 100 days after initial vaccination. Single-cell profiling of surface proteins, transcriptomes, and chromatin accessibility implicates transcription factors in the erythroblast-transformation-specific (ETS) family as shaping these long-lasting signatures, primarily in classical monocytes but also in CD8 + naive-like T cells. These cell-type-specific signatures are elevated at baseline in high-antibody responders in an independent vaccination cohort, suggesting that antigen-agnostic baseline immune states can be modulated by vaccine antigens alone to enhance future responses. Competing Interests: Declaration of interests R.G.v.d.M. is a former employee of and holds shares in the GSK group of companies. B.S. is a former SomaLogic, Inc. (Boulder, CO, USA), employee and a company shareholder. J.S.T. serves on the scientific advisory boards of CytoReason, Immunoscape, and the Human Immunome Project. (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu